It's perfectly normal for stocks to retrench after substantial gains, and that occurred earlier today, now we could be set to go substantially higher. Something else that's occurring right now has to do with the personnel found at brokerages, MM's, etc. for the most part senior management is on vacation, and probably will be through at least New Year's, if not all of next week. That being the case, my old broker used to say, the kids are in charge of the store, and they like to play.
I believe that if our cream is effective, we're dramatically under priced, but if is a huge word even if only comprised of two letters. It's up to the company to prove that their pre-clinical work is valid when actually used on people. While I'd be surprised of no one has ever tried it, or a very similar formulation, but it's not documented. I'm hoping the Phase 2 is not a blinded trial, if that's the case we could routinely see updates of what's happening.
I don't believe the company has ever stated they believed the cream is the cure for psoriasis, I'm unsure if any of the drugs with all their negative side effects cure it if their use is stopped, but it should greatly reduce the psoriasis while it continues to be used. The same is probably true of treatment of acne, etc.
Back when I was a kid I routinely saw a dermatologist for acne, much has changed in the past 50 years or so and while treatment is better, they still don't have a cure. I believe our cream may be a good treatment, but again not a cure. The reality is, it doesn't have to be, billion dollar products often don't cure, rather they control, and that's equally true for diseases as deadly as cancer and those as much a nuance as acne, the flu, or a headache.
With a little over 2 days remaining in the trading year it would be nice to end at or near highs. I certainly still intend to sell a few share for a tax loss by Tuesday, but it's far from my total holdings, and I'm happy not to have sold it previously at much lower prices. I don't know that next year we'll see new all time highs, but if some efficacy is seen in some of the earliest patients in the Phase 2 Trial, I certainly believe over a dollar possible in the coming year.
Happy New Year's all,
Gary
